Bioequivalence and the immunogenicity of biopharmaceuticals (Q34742161)

4 August 2017

1 reference

title

Bioequivalence and the immunogenicity of biopharmaceuticals (English)

1 reference

4 August 2017

Huub Schellekens

1

1 reference

PubMed ID

12119747

4 August 2017

language of work or name

1 reference

1 June 2002

1 reference

Nature Reviews Drug Discovery

4 August 2017

1 reference

4 August 2017

1

1 reference

4 August 2017

6

1 reference

4 August 2017

457-462

1 reference

https://scigraph.springernature.com/pub.10.1038/nrd818

4 August 2017

0 references

cites work

Factor VIII immunogenicity

1 reference

Immunogenicity and allergenic potential of animal and human insulins

31 March 2020

1 reference

IgG antibody response to polyethylene glycol-modified adenosine deaminase in patients with adenosine deaminase deficiency

31 March 2020

1 reference

[Neutralizing antibodies against salmon calcitonin. The cause of a treatment failure in Paget's disease]

31 March 2020

1 reference

Human pituitary growth hormone (hGH) therapy in growth hormone deficiency

31 March 2020

1 reference

Formation of neutralizing antibodies against natural interferon-beta, but not against recombinant interferon-gamma during adjuvant therapy for high-risk malignant melanoma patients

31 March 2020

1 reference

Treatment of malignant carcinoid tumors with recombinant interferon alfa-2b: development of neutralizing interferon antibodies and possible loss of antitumor activity

31 March 2020

1 reference

Immunoregulation and blocking antibodies induced by interferon beta treatment in MS

31 March 2020

1 reference

Interferon alfacon-1: a review of its pharmacology and therapeutic efficacy in the treatment of chronic hepatitis C.

31 March 2020

1 reference

Development of antibodies to unprotected glycosylation sites on recombinant human GM-CSF

31 March 2020

1 reference

The structure of human interferon-beta: implications for activity

31 March 2020

1 reference

Interferon antibodies in patients with infectious diseases. Anti-interferon antibodies

31 March 2020

1 reference

Treatment-induced antibodies to interleukin-2.

31 March 2020

1 reference

Neutralizing interferon beta antibodies in melanoma patients treated with recombinant and natural interferon beta

31 March 2020

1 reference

Role of aggregated human growth hormone (hGH) in development of antibodies to hGH

31 March 2020

1 reference

Formation of neutralizing antibodies during intranasal synthetic salmon calcitonin treatment of Paget's disease

31 March 2020

1 reference

Safety of repeated intermittent courses of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis.

31 March 2020

1 reference

Correlation between factor VIII genotype and inhibitor development in hemophilia A.

31 March 2020

1 reference

Immunogenicity of intraperitoneal insulin infusion using programmable implantable devices

31 March 2020

1 reference

Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin

31 March 2020

1 reference

Augmentation of hormonal activities with antibodies from cattle immunized with a combination of synthetic and recombinant growth hormone peptide.

31 March 2020

1 reference

Engineering of a mini-trichosanthin that has lower antigenicity by deleting its C-terminal amino acid residues

31 March 2020

1 reference

Recombinant staphylokinase variants with altered immunoreactivity. I: Construction and characterization

31 March 2020

1 reference

Towards a quantitative model of immunogenicity: counting pathways in sequence space.

31 March 2020

1 reference

Analysing structure-function relationships with biosensors

31 March 2020

1 reference

Comparative immunogenicity and thrombolytic properties toward arterial and venous thrombi of streptokinase and recombinant staphylokinase in baboons.

31 March 2020

1 reference

Nonclinical safety evaluation of biotechnologically derived pharmaceuticals

31 March 2020

1 reference

Comparison of the immunogenicity of recombinant and pituitary human growth hormone in rhesus monkeys

31 March 2020

1 reference

Immunogenicity of biopharmaceuticals in laboratory animals

31 March 2020

1 reference

The potential immunogenicity of human insulin and insulin analogues evaluated in a transgenic mouse model

31 March 2020

1 reference

'Biogenerics': the off-patent biotech products

31 March 2020

1 reference

Gonadotropin-releasing hormone (GnRH) antibodies formation in hypogonadotropic azoospermic men treated with pulsatile GnRH--diagnosis and possible alternative treatment

31 March 2020

1 reference

Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma

31 March 2020

1 reference

Development of anti-human chorionic gonadotropin antibodies in patients with hypogonadotropic hypogonadism. A study of four patients.

31 March 2020

1 reference

Neutralising antibodies to granulocyte-macrophage colony stimulating factor (GM-CSF) in carcinoma patients following GM-CSF combination therapy

31 March 2020

1 reference

Formation of antibodies to synthetic human calcitonin during treatment of Paget's disease

31 March 2020

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Clinical experience with Somatonorm.

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/NRD818

1 reference

PubMed ID

12119747

Dimensions Publication ID

4 August 2017

0 references

1 reference

PubMed ID

12119747